Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 4;105(23):1806-13.
doi: 10.1093/jnci/djt299. Epub 2013 Oct 30.

Secular trends in colon and rectal cancer relative survival

Affiliations
Free PMC article

Secular trends in colon and rectal cancer relative survival

Carolyn M Rutter et al. J Natl Cancer Inst. .
Free PMC article

Abstract

Background: Treatment options for colorectal cancer (CRC) have improved substantially over the past 25 years. Measuring the impact of these improvements on survival outcomes is challenging, however, against the background of overall survival gains from advancements in the prevention, screening, and treatment of other conditions. Relative survival is a metric that accounts for these concurrent changes, allowing assessment of changes in CRC survival. We describe stage- and location-specific trends in relative survival after CRC diagnosis.

Methods: We analyzed survival outcomes for 233965 people in the Surveillance Epidemiology and End Results (SEER) program who were diagnosed with CRC between January 1, 1975, and December 31, 2003. All models were adjusted for sex, race (black vs white), age at diagnosis, time since diagnosis, and diagnosis year. We estimated the proportional difference in survival for CRC patients compared with overall survival for age-, sex-, race-, and period-matched controls to account for concurrent changes in overall survival using two-sided Wald tests.

Results: We found statistically significant reductions in excess hazard of mortality from CRC in 2003 relative to 1975, with excess hazard ratios ranging from 0.75 (stage IV colon cancer; P < .001) to 0.32 (stage I rectal cancer; P < .001), indicating improvements in relative survival for all stages and cancer locations. These improvements occurred in earlier years for patients diagnosed with stage I cancers, with smaller but continuing improvements for later-stage cancers.

Conclusions: Our results demonstrate a steady trend toward improved relative survival for CRC, indicating that treatment and surveillance improvements have had an impact at the population level.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative relative survival among women aged 60 to 69 years diagnosed with colorectal cancer in 1980 (solid lines), 1990 (dashed lines) and 2000 (dotted lines), based on models that adjust for sex, race, age, year of diagnosis, and time since diagnosis.

References

    1. de Gramont A, Chibaudel B, Larsen AK, Tournigand C, Andre T, Gercor French Oncology Research Group. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer. 2011;10(4):218–226. - PubMed
    1. Graham JS, Cassidy J. Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther. 2012;12(1):99–109. - PubMed
    1. Adjuvant Therapy for Patients with Colon and Rectum Cancer. NIH Consensus Development Conference Statement, April 16–18, 1990. http://consensus.nih.gov/1990/1990adjuvanttherapycolonrectalcancer079htm... Accessed September 27, 2013. - PubMed
    1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 28 2000;343(13):905–914. - PubMed
    1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30. - PubMed

Publication types